Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Completes Acquisition of Decipher Biosciences

Veracyte Completes Acquisition of Decipher Biosciences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

Veracyte has a huge momentum run in 2021 thanks to accelerating operating and stock market momentum. I like the secular growth potential, yet fear that investors have gotten a bit too enthusiastic.

Veracyte: Not Too Excited After Momentum Run

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q4 2020 Results - Earnings Call Transcript

Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which missed the estimate of ($0.11).

Veracyte: Q4 Earnings Insights

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Veracyte Inc (NASDAQ: VCYT) has priced an upsized underwritten public offering of around 7.4 million common shares at $74 per share, with gross proceeds of approximately $550 million. Earlier, the company announced the equity offering of $400 million.

Veracyte Raises $550M In Upsized Equity Offering For Decipher Biosciences Acquisition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock

Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock

Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.

Veracyte Seeks To Raise $400M To Fund Decipher Biosciences Deal

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of $400.0 million in shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million in shares of its common stock at the public offering price, less underwriting discounts and commissions. Veracyte inte

Veracyte Announces Proposed Public Offering of Common Stock

Veracyte Inc (NASDAQ: VCYT) has agreed to acquire Decipher Biosciences, a precision oncology company focused on urologic cancers, further solidifying Veracyte's position in the genomic cancer diagnostics market.

Veracyte Scoops Up Decipher Biosciences For $600M, Reports Fourth Quarter Interim Results

SOUTH SAN FRANCISCO, Calif., & SAN DIEGO, Calif.--(BUSINESS WIRE)--Veracyte To Acquire Decipher Biosciences

Veracyte to Acquire Decipher Biosciences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Veracyte (VCYT) in Focus: Stock Moves 7% Higher

Bayer AG

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte's Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients' tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive i

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

Veracyte has been able to show a strong recovery after struggling through the COVID-19 headwinds of Q2. Now, the company is looking to fill the gap and surpass 2019's numbers. I take a look at the company's impressive Q3 earnings and discuss why I believe we will see this momentum carry into 2021.

Veracyte: A Strong Recovery Turning Into Strong Growth In The Midst Of A Pandemic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte received ISO 13485:2016 certification for the company's in vitro diagnostics Quality Management System.

Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

News for Veracyte Stock (VCYT)